Saratov JOURNAL of Medical and Scientific Research
Home

Clinical features of post-COVID syndrome in patients with carbohydrate metabolism disorders

Year: 2024, volume 20 Issue: №1 Pages: 28-33
Heading: Internal Diseases Article type: Original article
Authors: Savchuk K.S.
Organization: Saint-Petersburg Pasteur Institute, St. Petersburg, Russia
Summary:

Objective: clinical characteristics of patients with carbohydrate metabolism disorders (CDM) in the post-COVID period. Material and methods. 72 people with CDM in the post-COVID period were examined. Results. When detailing complaints, the incidence of respiratory symptoms in patients with impaired glucose tolerance (IGT) and diabetes mellitus (DM) was comparable. In both groups, nonspecific (general weakness) and neurological (memory deterioration, sleep disturbances, decreased vital activity) symptoms predominated. The development of NUD in the post-COVID period was facilitated by such risk factors as age >45 years, body mass index >25 kg/m2, family history of type 2 diabetes, hypertension. The most common concomitant diseases were overweight and obesity — in 64 (88.9%) patients, dyslipidemia — in 44 (61.1%), hypertension — in 32 (44.4%). In the group of patients with IGT, the frequency of re-infection with SARS-CoV-2 was higher compared to the group of patients with diabetes, and there was a tendency for the course to become more severe with re-infection. Conclusion. In the post-COVID period, patients with IGT and diabetes are more likely to have nonspecific and neurological complaints, while identified NDEs can aggravate the course of concomitant diseases and lead to re-infection with SARS-CoV-2.

Keywords: diabetes mellitus, impaired glucose tolerance, post-COVID patients, SARS-CoV-2 infection

Bibliography:
1. Dedov II, Shestakova MV, Mayorov AYu, et al. Algorithms for specialized medical care for patients with diabetes mellitus. Moscow, 2009; 231 p. DOI: https://doi.org/10.14341/DM13042
2. Huang Y, Cai X, Mai W, et al. Association between prediabetes and risk of cardiovascular disease and all-cause mortality: Systematic review and meta-analysis. BMJ. 2016; 355: i5953. DOI: 10.1136/bmj.i5953
3. IDF. IDF Diabetes Atlas. Eighth edition. 2021. URL: https://diabetesatlas.org/IDF_Diabetes_Atlas_10e_interactive_ EN/(26 Jan 2023).
4. Pal R, Joshi A, Bhadada SK, et al. Endocrine follow-up during post-acute COVID-19: Practical recommendations based on available clinical evidence. Endocr Pr. 2022; 28 (4): 425-32. DOI: 10.1016/j.eprac.2022.02.003
5. Khunti K, Del Prato S, Mathieu C, et al. COVID-19, hyperglycemia, and new-onset diabetes. Diabetes Care. 2021; 44(12): 2645-55. DOI: 10.2337/dc21-1318
6. Banerjee M, Pal R, Dutta S. Risk of incident diabetes post-COVID-19: A systematic review and meta-analysis. Prim Care Diabetes. 2022; 16 (4): 591-3. DOI: 10.1016/j.pcd. 2022.05.009
7. Birabaharan M, Kaelber DC, Pettus JH, Smith DM. Risk of new-onset type 2 diabetes in 600055 people after COVID-19: A cohort study. Diabetes Obes Metab. 2022; 24 (6): 1176-9. DOI: 10.1111/dom.14659
8. Gavkare AM, Nanaware N, Rayate AS, et al. COVID-19 associated diabetes mellitus: A review World J Diabetes. 2022; 13 (9): 729-37. DOI: 10.4239/wjd.v13.i9.729
9. Savchuk KS, Ryabova LV, Dobrynina MA. Clinical and immunological features of the course of post-COVID syndrome in patients with type 2 diabetes mellitus. From clinical recommendations to real practice: an interdisciplinary collection of scientific and practical works. Chelyabinsk, 2023; p. 108-10.
10. Trigolosova IV, Praskurnichy EA, Khodeeva TYu, Khizhnyak NN. Diabetes mellitus and obesity in coronavirus infection (COVID-19): Epidemiology, pathogenesis, approaches to therapy. Clinical Bulletin of the FMBC named after A.I. Burnazyan. 2022; (2): 54-9.
11. Ivanitskaya АА, Kopieva ES, Popugailo MV. Analysis of some features of the pathogenesis of concomitant diseases and complications of COVID-19. Academic science — problems and achievements: Materials of the XXVI international scientific and practical conference. Morrisville: LuluPress, Inc., 2021; p. 13-9.
12. Soriano JB, Murthy S, Marshall JO A clinical case definition of post-COVID-19 condition by a Delphi consensus. Lancet Infect Dis. 2022; 22 (4): 102-7. DOI: 10.1016/S1473-3099(21)00703-9
13. Lippi G, Sanchis-Gomar F, Henry BM. COVID-19 and its long-term sequelae: What do we know in 2023? Pol Arch Intern Med. 2023; 133 (4): 16402. DOI: 10.20452/pamw
14. Safronova EA, Ryabova LV, Zurochka AV Clinical and immunological characteristics of patients with acute coronary syndrome who have had COVID-19. Bulletin of the Ural Medical Academic Science. 2023; 20 (1-2): 31-9. DOI: 10.22138/2500-0 918-2023-20-1-31-39
15. Ashurova NG. Hyperglycemia as a risk factor for cardiovascular complications. Miasto Przysztosci. 2023; (35): 301-9.
16. On approval of the procedure for conducting dispensary observation of adults: Order of the Ministry of Health of the Russian Federation dated March 15, 2022 N168n. URL: http://publication.pravo.gov.ru/Document/ View/0001202204210027?ysclid=ltwlt7m8gy 192345193 (12 Feb 2024).
17. Chronic kidney disease: Clinical guidelines. 2023. URL: https://cr.minzdrav.gov.ru/schema/469_2 (12 Feb 2024).
18. Non-alcoholic fatty liver disease in adults: Clinical guidelines. 2022. URL: https://cr.minzdrav.gov.ru/sche-ma/748_1 (12 Feb 2024).
19. Norgard BM, Zegers FD, Juhl СВ, et al. Diabetes mellitus and the risk of post-acute COVID-19 hospitalizations — a nationwide cohort study. Diabet Med. 2023; 40 (2): e14986. DOI: 10.1111/dme.14986

AttachmentSize
2024_01_028-033.pdf536.74 KB
All articles of the authors: Savchuk K.S.

No votes yet